Skip to content

DIGITal mOnitoring afTer Af abLation

A Study of Intermittent Photoplethysmography Based Rhythm Monitoring for Detection of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05486364
Acronym
DIGITOTAL
Enrollment
100
Registered
2022-08-03
Start date
2021-12-20
Completion date
2023-08-15
Last updated
2023-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Atrial Fibrillation Recurrent, PVI

Keywords

Atrial Fibrillation, PVI, Atrial ablation, pulmonary vein isolation, PPG, Photoplethysmography, Digital Health

Brief summary

Recurrence of atrial fibrillation (AF) after a pulmonary vein isolation (PVI) procedure is frequent. Current follow up with Holter monitoring and electrocardiograms (ECG) during outpatient clinic consultations cover only short time stretches and require hospital visits. Mobile health solutions with rhythm monitoring using photoplethysmography (PPG) technology on a smartphone could extend rhythm monitoring time, while lowering hospital visits and cost. This study aims to compare the performance of a digital health solution using PPG technology on a smartphone versus the current standard of care to monitor for AF recurrence after a PVI procedure.

Interventions

DIAGNOSTIC_TESTDigital Monitoring

Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.

DIAGNOSTIC_TESTStandard of care

Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).

Sponsors

Ziekenhuis Oost-Limburg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is scheduled for an ablation procedure for AF, at least 4 weeks after the inclusion. * Subject provides informed consent. * Subject understands and agrees to comply with planned study procedures. * Subject is able to perform measurements of the heart rhythm using the FibriCheck application at home.

Exclusion criteria

* Insufficient cognitive or comprehensive level of Dutch to participate to the trial. * No access to a smartphone or unable to perform FibriCheck measurements at home. * Pacemaker.

Design outcomes

Primary

MeasureTime frame
AF detection rate with PPG-monitoring vs standard of care monitoring after the blanking period in the first-year post AF ablation1 year

Secondary

MeasureTime frame
The number and dispersion of PPG measurements needed to achieve similar sensitivity with intermittent one-minute PPG measurements compared to one 24h-Holter.1 year
Sensitivity, specificity and accuracy of PPG rhythm monitoring for AF detection during 24h-Holter monitoring on PPG measurement level.1 year
Proportion of confirmed symptom-rhythm correlations by PPG-monitoring vs standard care monitoring in patients who report symptoms on outpatient consultations.1 year
Predictive value of AF detection with PPG during blanking period for AF recurrence.1 year
Time to detection of AF after PVI (and after the blanking period) with PPG monitoring vs standard of care monitoring.1 year

Other

MeasureTime frameDescription
Patient compliance with PPG measurements1 year
Subanalysis of primary outcome 1 and secondary outcomes 1,2 and 31 yearExcluding ECG measurements that were triggered by AF detection with PPG.
Evaluation of AF-burden quantification by intermittent PPG measurements.1 year

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026